Navigation Links
Schering-Plough Shareholders Approve Merger With Merck
Date:8/7/2009

BOSTON, Aug. 7 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) announced the voting results of a special shareholders meeting today regarding the proposed merger with Merck & Co., Inc. More than 99 percent of votes cast voted to approve the merger agreement, with more than 78 percent of common shares voting.

"Today's vote by our shareholders reflects the potential they see to create a strong global health care leader by combining these two companies," said Fred Hassan, Schering-Plough chairman and CEO. "After six years of transformation under our Action Agenda, our Schering-Plough colleagues can be very proud of the strengths and diversity we have created. As we move closer to realizing this merger, we will continue to focus on driving our business and advancing our strong late-stage pipeline until closing."

The merger, which is expected to close in the 2009 fourth quarter, is subject to the satisfaction of customary closing conditions and regulatory approvals, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, as well as clearance by the European Commission under the EC Merger Regulation and certain other foreign jurisdictions.

In the merger, Schering-Plough shareholders will receive 0.5767 of a common share in the combined company (to be called Merck) and $10.50 in cash for each Schering-Plough common share. Each Merck share will become a share of the combined company. Following completion of the merger, it is anticipated that the combined company will continue the dividend policies of Merck, currently a quarterly cash dividend of $0.38 per common share (subject to declaration by the board of directors and a variety of factors including business and financial considerations).

DISCLOSURE NOTICE:

The information in this press release and other written reports and oral statements made from time to time by the company may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and are based on current expectations or forecasts of future events. You can identify these forward-looking statements by their use of words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "project," "intend," "plan," "potential," "will," and other similar words and terms. In particular, forward-looking statements include statements about the timing and potential benefits of the proposed merger between Merck and Schering-Plough; Schering-Plough's and the combined company's strengths; the trending of Schering-Plough's pipeline and business; and other statements that are not historical facts. Actual results may vary materially from the company's forward-looking statements, and there are no guarantees about the performance of Schering-Plough stock or Schering-Plough's business or the combined company's business. Schering-Plough does not assume the obligation to update any forward-looking statement.

A number of risks and uncertainties could cause actual results to differ materially from forward-looking statements, including, among other uncertainties, market viability of the company's and Merck's marketed products and pipeline projects; market forces; economic factors such as interest rate and exchange rate fluctuations; the outcome of contingencies such as litigation and investigations; product availability; patent and other intellectual property protection; current and future branded, generic or over-the-counter competition; the regulatory process (including product approvals, labeling and post-marketing actions); scientific developments relating to marketed products or pipeline projects; media and societal reaction to such developments; and the ability of Schering-Plough and Merck to obtain governmental approvals of the merger on the proposed terms and schedule. For further details of these and other risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A "Risk Factors" in the company's second quarter 2009 10-Q, filed July 24, 2009 and "Risk Factors" in the joint merger proxy/prospectus dated June 25, 2009.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... , ... Lajollacooks4u has become a rising hotspot for specialized team building events ... attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, Qualcomm and Elsevier, have traveled ... , Each event kicks off with an olive oil and salt-tasting competition. From ...
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of the Fitzmaurice ... surgery and surgery of the hand by the National Board of Physicians and ... above and beyond in his pursuit of providing the most comprehensive, effective treatment ...
(Date:5/25/2016)... ... , ... WEDI, the nation’s leading authority on the use of health IT ... been named by the WEDI Board of Directors as WEDI’s president and CEO. Stellar ... more than 35 years of experience in healthcare, association management and organizational leadership, Stellar ...
(Date:5/24/2016)... Worcester, Mass. (PRWEB) , ... May 24, 2016 ... ... including heart attacks, diabetes, and traumatic injuries, will be accelerated by research at ... skin cells into engines of wound healing and tissue regeneration. , The novel ...
Breaking Biology Technology:
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
Breaking Biology News(10 mins):